These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31673107)

  • 1. Structure Based Multitargeted Molecular Docking Analysis of Selected Furanocoumarins against Breast Cancer.
    Acharya R; Chacko S; Bose P; Lapenna A; Pattanayak SP
    Sci Rep; 2019 Oct; 9(1):15743. PubMed ID: 31673107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer.
    Rasul HO; Aziz BK; Ghafour DD; Kivrak A
    J Mol Model; 2021 Dec; 28(1):17. PubMed ID: 34962586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
    Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
    Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
    Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
    J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DESIGN, SYNTHESIS, MOLECULAR DOCKING AND ANTI-BREAST CANCER ACTIVITY OF NOVEL QUINAZOLINONES TARGETING ESTROGEN RECEPTOR α.
    Ahmed MF; Youns M; Belal A
    Acta Pol Pharm; 2016; 73(1):115-27. PubMed ID: 27008806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
    Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
    J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Maruthanila VL; Elancheran R; Mirunalini S
    Curr Comput Aided Drug Des; 2022; 18(3):196-212. PubMed ID: 35598239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
    Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
    Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach.
    Rasul HO; Aziz BK; Ghafour DD; Kivrak A
    Mol Divers; 2023 Jun; 27(3):1141-1162. PubMed ID: 35737256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure Based docking studies towards exploring potential anti-androgen activity of selected phytochemicals against Prostate Cancer.
    Singh AN; Baruah MM; Sharma N
    Sci Rep; 2017 May; 7(1):1955. PubMed ID: 28512306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the Anti-Cancer Potential of Onoceranoid Triterpenes from
    Hardianto A; Mardetia SS; Destiarani W; Budiman YP; Kurnia D; Mayanti T
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF-7/SC Breast Cancer Cells.
    To NB; Truong VN; Ediriweera MK; Cho SK
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico docking studies of selected flavonoids--natural healing agents against breast cancer.
    Suganya J; Radha M; Naorem DL; Nishandhini M
    Asian Pac J Cancer Prev; 2014; 15(19):8155-9. PubMed ID: 25338999
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
    J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An In silico Approach to Identify High Affinity Small Molecule Targeting m-TOR Inhibitors for the Clinical Treatment of Breast Cancer.
    Patidar K; Panwar U; Vuree S; Sweta J; Sandhu MK; Nayarisseri A; Singh SK
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1229-1241. PubMed ID: 31030499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical Characterization,
    Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
    Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.